Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Manipulating the gut microbiota via prebiotic glycans to influence the efficacy of PD-1-blockade immunotherapy

FY 2022-23

Summary
Cancer immunotherapy is a powerful treatment for one of the deadliest diseases. However, 60-70% of patients do not respond to this treatment. Recent research has revealed that the composition of the gut microbiota is linked to cancer patients’ response to PD-1 blockade immunotherapy. Moreover, data in mouse models suggest that modulating the microbiota is an attractive strategy to re-sensitize cancer patients to immunotherapy. The composition of the gut microbiota relies on many factors, with diet playing a key role. A diet rich in nondigestible carbohydrates, or glycans, has been associated with a positive response to cancer immunotherapy. In particular, the diet-derived glycan inulin has been shown to promote the growth of bacteria associated with positive immunotherapy outcome in a mouse cancer model. We hypothesize that glycan-consuming gut bacteria drive the positive response to PD-1 blockade. Following a screen of glycan candidates in a mouse model, we propose to identify those promoting growth of bacteria associated with positive PD-1 blockade response. Using inulin as a framework, we will first identify bacterial inulin consumers (inulin+) in stool from PD-1 unresponsive cancer patients and determine their influence on treatment outcomes with the following aims: (1) Label, sort, and isolate inulin-consuming bacteria from a cancer patient donor fecal sample; (2) Characterize the metabolic mechanisms of inulin metabolism and determine if the metabolic outputs of inulin-consumers have immunomodulatory properties; (3) Administer the identified inulin-consumers in a mouse model of PD-1 checkpoint immunotherapy. Starting with inulin, this project will address if enrichment of glycan-consuming gut bacteria can improve an individual’s response to cancer immunotherapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486261
Name
Prattico Catherine V
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Manipulating the gut microbiota via prebiotic glycans to influence the efficacy of PD-1-blockade immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anoxic Cell Sorting; Cancer; Cancer Immunotherapy; Glycans; Microbiome; Prebiotics
Abstract
Cancer immunotherapy is a powerful treatment for one of the deadliest diseases. However, 60-70% of patients do not respond to this treatment. Recent research has revealed that the composition of the gut microbiota is linked to cancer patients’ response to PD-1 blockade immunotherapy. Moreover, data in mouse models suggest that modulating the microbiota is an attractive strategy to re-sensitize cancer patients to immunotherapy. The composition of the gut microbiota relies on many factors, with diet playing a key role. A diet rich in nondigestible carbohydrates, or glycans, has been associated with a positive response to cancer immunotherapy. In particular, the diet-derived glycan inulin has been shown to promote the growth of bacteria associated with positive immunotherapy outcome in a mouse cancer model. We hypothesize that glycan-consuming gut bacteria drive the positive response to PD-1 blockade. Following a screen of glycan candidates in a mouse model, we propose to identify those promoting growth of bacteria associated with positive PD-1 blockade response. Using inulin as a framework, we will first identify bacterial inulin consumers (inulin+) in stool from PD-1 unresponsive cancer patients and determine their influence on treatment outcomes with the following aims: (1) Label, sort, and isolate inulin-consuming bacteria from a cancer patient donor fecal sample; (2) Characterize the metabolic mechanisms of inulin metabolism and determine if the metabolic outputs of inulin-consumers have immunomodulatory properties; (3) Administer the identified inulin-consumers in a mouse model of PD-1 checkpoint immunotherapy. Starting with inulin, this project will address if enrichment of glycan-consuming gut bacteria can improve an individual’s response to cancer immunotherapy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Prattico, Catherine V
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~